Patent intelligence · US
US 12318386
Combination of XPO1 inhibitors and second agents for the treatment of prostate cancer
Combination of XPO1 inhibitors and second agents for the treatment of prostate cancer
Patent details — US 12318386
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 3, 2025
- Expiration
- May 29, 2045
- Applicant
- Karyopharm Therapeutics Inc.
- Claims
- 8
- CPC classes
- A61K, A61K31/4166, A61K31/433, A61K31/506
Quick answer
US 12318386 (Combination of XPO1 inhibitors and second agents for the treatment of prostate cancer) is held by Karyopharm Therapeutics Inc.. Status: granted. Granted Jun 3, 2025. Expires May 29, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Karyopharm Therapeutics Inc.
- Grant date
- Expiration
- Claims
- 8
- CPC classes
- A61K, A61K31/4166, A61K31/433, A61K31/506, A61K31/573, A61K31/58
More from Karyopharm Therapeutics Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12371420
Polymorphs of Selinexor
granted -
US 12331040
Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
granted -
US 12291508
Hydrazide containing nuclear transport modulators and uses thereof
granted -
US 11945794
Nuclear transport modulators and uses thereof
granted -
US 11807629
Polymorphs of Selinexor
granted -
US 11787771
Hydrazide containing nuclear transport modulators and uses thereof
granted -
US 11753401
Polymorphs of Selinexor
granted
Frequently asked questions
What is US patent 12318386?
US 12318386 (Combination of XPO1 inhibitors and second agents for the treatment of prostate cancer) is held by Karyopharm Therapeutics Inc.. Status: granted. Granted Jun 3, 2025. Expires May 29, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12318386?
Karyopharm Therapeutics Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 38 pharmaceutical patents for this assignee.
When does US 12318386 expire?
Our index shows an expiration date of May 29, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.